Nanopharmaceutics, Inc. Press Releases - EIN Presswire - Press Release Distribution Service

Published on September 1, 2026 - 13:00 GMT

Nanopharmaceutics Announces Issuance of U.S. Patent Covering Oral Triapine® Formulations and Methods of Treating Cancer

New patent further strengthens global intellectual property estate supporting Nanopharmaceutics 's lead program Triapine® in pancreatic cancer and glioblastoma TRON Group Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, September 1, 2026 /⁨EINPresswire …

Distribution channels: Healthcare & Pharmaceuticals Industry, Manufacturing ...

Published on January 15, 2026 - 22:00 GMT

Mark Cuban Cost Plus Drugs and Alchem Laboratories Announce Alliance to Advance Essential Medicines

DALLAS, TX, UNITED STATES, January 15, 2026 /⁨EINPresswire.com⁩/ -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and Alchem Laboratories Corporation (Alchem) today announced the formation of a strategic alliance to develop essential medicine …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on September 10, 2025 - 17:04 GMT

Nanopharmaceutics Announces Presentation of National Cancer Institute sponsored Phase I Study with Triapine at ESMO 2025

Phase I Study with Triapine + Lutetium Lu 177 Dotatate in patients with progressive well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs) TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, September 10, 2025 /⁨EINPresswire. …

Distribution channels: Chemical Industry, Companies ...

Published on September 3, 2025 - 21:41 GMT

Alchem Laboratories and Applied Pharmaceutical Innovation Forge Strategic Alliance to Advance Antimicrobial Programs

Alchem Laboratories and Applied Pharmaceutical Innovation (API) Forge Strategic Alliance to Advance Antimicrobial and Essential Medicines Programs ALACHUA, FL, UNITED STATES, September 3, 2025 /⁨EINPresswire.com⁩/ -- Alchem Laboratories Corporation (“ …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on July 18, 2025 - 20:10 GMT

Nanopharmaceutics Announces End of Patient Recruitment for NCI Phase II Study with Triapine for Neuroendocrine Tumors

Nanopharmaceutics Inc. Announces End of Patient Recruitment of NCI Phase II Clinical Study with Lutetium Lu 177 Dotatate +/- Triapine for Neuroendocrine Tumors TRON Group Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, July 18, 2025 /⁨EINPresswire.com⁩/ …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on July 1, 2025 - 13:45 GMT

TRON Group Inc. Transitions to OTCID Tier on OTC Markets

New Market Designation Reflects Higher Reporting Standards TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, July 1, 2025 /⁨EINPresswire.com⁩/ -- TRON Group Inc. (OTCID: TGRP) announced today its transition to the newly introduced OTCID tier on …

Distribution channels: Chemical Industry, Healthcare & Pharmaceuticals Industry ...

Published on May 9, 2025 - 14:55 GMT

Nanopharmaceutics Announces NanoDOX® Hydrogel will be Tested in The University of Western Australia Clinical Trial

Nanopharmaceutics Announces NanoDOX® Hydrogel will be Tested in Patients with Genital Mycoplasmas in The University of Western Australia Phase II Clinical Trial TRON Group Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, May 9, 2025 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Chemical Industry, Companies ...

Published on April 1, 2025 - 17:04 GMT

Nanopharmaceutics Inc. Announces Initiation of Clinical Study of Triapine + Radiation for Glioblastoma or Astrocytoma

Initiation of Clinical Study Testing the Addition of an Anti-Cancer Drug, Triapine®, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma TRON Group Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, April 1, 2025 /⁨EINPresswire.com⁩/ -- …

Distribution channels: Banking, Finance & Investment Industry, Chemical Industry ...

Published on December 12, 2024 - 18:27 GMT

PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels

Nanopharmaceutics Announces Preprint “PRX-3140, a 5-HT4 Agonist and Sigma-1 Agonist/Antag., Modulates Glucocorticoid Insulin Suppression and Cortisol Levels” TRON Pharmaceuticals Inc (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, December 12, 2024 /⁨ …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on October 11, 2024 - 12:00 GMT

Nanopharmaceutics Announces Initiation of Clinical Study of Oral Tetrathiomolybdate Capsules in Breast Cancer Patients

Nanopharmaceutics Announces Initiation of Phase 1b / 2 Clinical Study of Oral Tetrathiomolybdate Capsules in Triple Negative Breast Cancer Patients TRON Pharmaceuticals, Inc. (OTCMKTS:TGRP) ALACHUA, FL, UNITED STATES, October 11, 2024 /⁨EINPresswire.com …

Distribution channels: Chemical Industry, Companies ...